Chris Dockendorff

Chris is the CSO & CEO of Function Therapeutics, a young preclinical firm developing anti-inflammatory and anti-thrombotic compounds with a focus on allosteric GPCR modulators. He previously served on the faculty of Marquette University and was a research scientist at the Broad Institute and NPS Pharmaceuticals. Originally trained as an organic chemist, Chris’ diverse research has included synthetic methods, medicinal chemistry, and GPCR pharmacology.